SRR13311168
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.560
- GLYCOLYSIS+0.490
- HYPOXIA+0.490
- E2F_TARGETS+0.460
- MTORC1_SIGNALING+0.450
- G2M_CHECKPOINT+0.440
- CHOLESTEROL_HOMEOSTASIS+0.430
- ANDROGEN_RESPONSE+0.420
- P53_PATHWAY+0.400
- ESTROGEN_RESPONSE_EARLY+0.390
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.330
- ALLOGRAFT_REJECTION-0.300
- INTERFERON_GAMMA_RESPONSE-0.250
- MYC_TARGETS_V2-0.210
- PANCREAS_BETA_CELLS-0.210
- HEDGEHOG_SIGNALING-0.100
- SPERMATOGENESIS-0.070
- MYOGENESIS-0.020
- WNT_BETA_CATENIN_SIGNALING-0.010
- KRAS_SIGNALING_DN+0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-4Z-AA7Y-01A-11R-A39I-07 | — | — | 0.833 |
| 2 | MNG590 | — | — | 0.825 |
| 3 | MNG1079 | — | — | 0.819 |
| 4 | DRR168580 | — | — | 0.818 |
| 5 | TCGA-68-7756-01A-11R-2125-07 | — | cohortSQ1 | 0.816 |
| 6 | DRR168536 | — | — | 0.811 |
| 7 | TCGA-66-2734-01A-01R-0980-07 | — | cohortSQ1 | 0.809 |
| 8 | MNG1023 | — | — | 0.809 |
| 9 | 8D30F824-25B9-43DB-BD39-2C9C790509DD | — | — | 0.808 |
| 10 | BS_23M72ABG | Meningioma | — | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.560 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.490 | Inavolisib | — uncovered |
| HYPOXIA | 0.490 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.440 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.400 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.380 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.350 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.320 | Temsirolimus | — uncovered |
| PEROXISOME | 0.300 | Idelalisib | — uncovered |